# EDGAR Filing Document

**Accession Number:** 0001855655
**File Stem:** 0001855655-25-000011
**Filing Date:** 2025-8
**Character Count:** 15486
**Document Hash:** e7950565edc650b9326eb6fb0143daed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001855655-25-000011.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001855655-25-000011

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Paradigm Biocapital Advisors LP
- **CENTRAL INDEX KEY:** 0001855655

**ORGANIZATION NAME:**
- **EIN:** 851451055
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-21950
- **FILM NUMBER:** 251277322

**BUSINESS ADDRESS:**
- **STREET 1:** 767 THIRD AVENUE, 17TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 646-970-2123

**MAIL ADDRESS:**
- **STREET 1:** 767 THIRD AVENUE, 17TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001855655

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Paradigm BioCapital Advisors LP

**Address:** 767 Third Avenue, New York, NY 10017

**Telephone number:** 646-970-2568

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-21950

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                  | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                     | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Immunovant, Inc.                | 45258J102 | 08/12/2024     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 804771           |                0 | FOR         |                         804771           | FOR                         |  |
| Cytokinetics, Incorporated      | 23282W605 | 05/14/2025     | To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |  81352           |                0 | FOR         |                          81352           | FOR                         |  |
| Insmed Incorporated             | 457669307 | 05/15/2025     | An advisory vote on the 2024 compensation of our named executive officers.                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 150672           |                0 | FOR         |                         150672           | FOR                         |  |
| BeiGene Ltd.                    | 07725L102 | 05/21/2025     | THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.                                                                                  | SECTION 14A SAY-ON-PAY VOTES | 467428           |                0 | AGAINST     |                         467428           | AGAINST                     |  |
| Merus N.V.                      | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      2.9562e+06  |                0 | FOR         |                              2.9562e+06  | FOR                         |  |
| Arcellx, Inc.                   | 03940C100 | 05/28/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.                                                 | SECTION 14A SAY-ON-PAY VOTES |      3.05211e+06 |                0 | FOR         |                              3.05211e+06 | FOR                         |  |
| Spyre Therapeutics, Inc.        | 00773J202 | 05/29/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES | 630473           |                0 | FOR         |                         630473           | FOR                         |  |
| Cogent Biosciences, Inc.        | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |      8.31588e+06 |                0 | FOR         |                              8.31588e+06 | FOR                         |  |
| MoonLake Immunotherapeutics     | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 117859           |                0 | FOR         |                         117859           | FOR                         |  |
| Olema Pharmaceuticals, Inc.     | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      5.7851e+06  |                0 | FOR         |                              5.7851e+06  | FOR                         |  |
| Crinetics Pharmaceuticals, Inc. | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;             | SECTION 14A SAY-ON-PAY VOTES |      1.49497e+06 |                0 | FOR         |                              1.49497e+06 | FOR                         |  |
| Disc Medicine, Inc.             | 254604101 | 06/11/2025     | To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES | 839713           |                0 | FOR         |                         839713           | FOR                         |  |
| Disc Medicine, Inc.             | 254604101 | 06/11/2025     | To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 839713           |                0 | ONE YEAR    |                         839713           | FOR                         |  |
| Janux Therapeutics, Inc.        | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                                                | SECTION 14A SAY-ON-PAY VOTES |      2.55434e+06 |                0 | FOR         |                              2.55434e+06 | FOR                         |  |
| Janux Therapeutics, Inc.        | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      2.55434e+06 |                0 | ONE YEAR    |                              2.55434e+06 | FOR                         |  |
| Ocular Therapeutix, Inc.        | 67576A100 | 06/11/2025     | To approve an advisory vote on named executive officer compensation.                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 909492           |                0 | AGAINST     |                         909492           | AGAINST                     |  |
| Arcutis Biotherapeutics, Inc.   | 03969K108 | 06/12/2025     | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      1.51921e+06 |                0 | AGAINST     |                              1.51921e+06 | AGAINST                     |  |
| Tarsus Pharmaceuticals, Inc.    | 87650L103 | 06/12/2025     | To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      2.0539e+06  |                0 | FOR         |                              2.0539e+06  | FOR                         |  |
| Tarsus Pharmaceuticals, Inc.    | 87650L103 | 06/12/2025     | To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes on the compensation of our named executive officers will be conducted of one, two or three years.                                     | SECTION 14A SAY-ON-PAY VOTES |      2.0539e+06  |                0 | ONE YEAR    |                              2.0539e+06  | FOR                         |  |
| Vaxcyte, Inc.                   | 92243G108 | 06/12/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 981715           |                0 | AGAINST     |                         981715           | AGAINST                     |  |
| Edgewise Therapeutics, Inc.     | 28036F105 | 06/13/2025     | Conduct an advisory vote on the compensation of our named executive officers.                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      5.19471e+06 |                0 | FOR         |                              5.19471e+06 | FOR                         |  |
| Edgewise Therapeutics, Inc.     | 28036F105 | 06/13/2025     | Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      5.19471e+06 |                0 | ONE YEAR    |                              5.19471e+06 | FOR                         |  |
| Apogee Therapeutics, Inc.       | 03770N101 | 06/17/2025     | Vote on the frequency of future advisory votes to approve our named executive officers compensation.                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES | 415796           |                0 | ONE YEAR    |                         415796           | FOR                         |  |
| Nuvalent, Inc.                  | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      3.69034e+06 |                0 | AGAINST     |                              3.69034e+06 | AGAINST                     |  |
| Viridian Therapeutics, Inc.     | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      2.09508e+06 |                0 | AGAINST     |                              2.09508e+06 | AGAINST                     |  |
| Revolution Medicines, Inc.      | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). | SECTION 14A SAY-ON-PAY VOTES |      3.389e+06   |                0 | FOR         |                              3.389e+06   | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Paradigm BioCapital Advisors LP

**By (Signature):** David Kim

**By (Printed Signature):** David Kim

**By (Title):** Chief Operating Officer and Chief Compliance Officer

**Date:** 07/28/2025